Theriva Biologics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-23.7M | $-25.7M | $-18.3M | $-19.7M | $-14.3M | $-10.0M | $-15.3M | $-13.4M |
| Depreciation & Amortization | $108.0K | $137.0K | $135.0K | $85.0K | $87.0K | $201.0K | $240.0K | $272.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $654.0K | $671.0K | $552.0K | $475.0K | $416.0K | $350.0K | $340.0K | $2.1M |
| Net Cash from Operating Activities | $-16.7M | $-16.9M | $-19.0M | $-19.1M | $-12.9M | $-12.2M | $-13.9M | $-17.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $35.0K | $1.0K | $202.0K | $116.0K | $14.0K | $9.0K | $0 | $7.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-35.0K | $-1.0K | $-202.0K | $-4.4M | $-14.0K | $-9.0K | $0 | $-7.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $18.2M | $5.5M | $625.0K | $-1.9M | $74.0M | $3.4M | $0 | $29.1M |
| Net Change in Cash | $1.4M | $-11.6M | $-18.6M | $-25.4M | $61.1M | — | — | — |
| Free Cash Flow | $-16.7M | $-16.9M | $-19.2M | $-19.2M | $-12.9M | $-12.2M | $-13.9M | $-17.3M |